Extemporaneously compounded liquid formulations of clofazimine
The International Journal of Tuberculosis and Lung Disease · 01.02.2023 · 27 (2) · 106-112
DOI: 10.5588/ijtld.22.0331 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 01.02.2023. Verfasst von R Taneja und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Alliance for TB drug Development (TB Alliance), New York, NY, USA. Hauptthemen laut MEDLINE: Clofazimine, Pharmaceutical Services, Drug Compounding. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Clofazimine (CFZ) is routinely used worldwide for the treatment of leprosy and TB. However, no liquid or dispersible tablet formulations of CFZ are currently available commercially for patients with challenges ingesting soft gelatin capsules or solid formulations. The aim of this research was to develop stable extemporaneous liquid formulations of CFZ that can be stored at room temperature for several weeks to enable practical dosing in the field. METHODS: Two formulations were prepared in syrup and sugar-free vehicles with CFZ tablets using a simple method that can be used in a routine pharmacy. Suspensions were stored at room temperature and at 30°C for 30 days. Formulation aliquots were tested on Days 0, 15 and 30 for appearance, pH, potency and microbial counts. RESULTS: Appearance remained unchanged during storage. The pH of both formulations was between 4.0 and 6.0. Potency was between 90% and 110% for 30 days in the syrup formulation and for 15 days in the sugar-free formulation. Microbial counts met United States Pharmacopeia limits for oral aqueous liquids and specific organisms were absent. CONCLUSIONS: A simple field-friendly method was successfully developed for the preparation of CFZ liquid formulations using commonly available ingredients. This will permit practical dosing and titration for children and other patients with swallowing challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Alliance for TB drug Development (TB Alliance), New York, NY, USA.
- Institute of Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, The Ohio State University, Columbus, OH, USA.
- JSAS Services Inc, Tucson, AZ, USA.
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- Metro TB Complex, Department of Health, Pretoria, South Africa.
- Institute for Safe Medication Practices, Plymouth Meeting, PA, USA.
Zitieren
APA
Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Hesseling, A. C., & Garcia-Prats, A. J. (2023). Extemporaneously compounded liquid formulations of clofazimine. The International Journal of Tuberculosis and Lung Disease, 27(2), 106-112. https://doi.org/10.5588/ijtld.22.0331
Vancouver
Taneja R, Nahata MC, Scarim J, Pande PG, Scarim A, Hoddinott G, et al. Extemporaneously compounded liquid formulations of clofazimine. The International Journal of Tuberculosis and Lung Disease. 2023;27(2):106-112. doi:10.5588/ijtld.22.0331
BibTeX
@article{Taneja2023,
author = {Taneja, R and Nahata, M C and Scarim, J and Pande, P G and Scarim, A and Hoddinott, G and Fourie, C L and Jew, R K and Schaaf, H S and Hesseling, A C and Garcia-Prats, A J},
title = {Extemporaneously compounded liquid formulations of clofazimine},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2023},
volume = {27},
number = {2},
pages = {106--112},
doi = {10.5588/ijtld.22.0331}
}
EUVIMED